Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 3

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 3
---
 right mix of experience, qualifications and skills and represent a mix of diverse experience, background and thought to contribute to our strategy and to the Board’s ability to perform its duties.

All of our directors are independent, except for Curran Simpson, our President and CEO, Kenneth T. Mills, the Chairman of the Board, and Allan M. Fox.

Ratification of Appointment of Independent Registered Public Accounting Firm: Please vote “For”(page20)

PricewaterhouseCoopers LLP (“PwC”) is an independent accounting firm with the breadth of expertise and knowledge necessary to effectively audit our business.

PwC has served as our independent registered public accounting firm since 2015.

Advisory Vote on Executive Compensation: Please vote “For”(page23)

Independent oversight by the Compensation Committee with the assistance of an independent external consultant.

Executive compensation targets are determined based on an annual peer group review and annual analysis of all elements of executive compensation for each executive.

Advisory Vote on the Frequency of Executive Compensation: Please vote “One Year”(page50)

On an advisory basis, to determine how often stockholders prefer to have an advisory vote on the compensation of executives (every year, every two years, or every three years).

An annual vote offers direct and immediate feedback on the Company’s compensation programs.

We have held advisory votes on executive officer compensation on an annual basis since 2019 based on our stockholders’ expressed preference for an annual say on pay at the 2019 annual meeting.

Approve the REGENXBIO Inc. 2025 Equity Incentive Plan: Please vote “For”(page51)

The Company has put forth an appropriately balanced equity incentive plan designed to attract and retain top talent and align their interests with the Company's long-term goals.

The proposed equity incentive plan was crafted to align with current executive compensation trends and recommended best practices.

About REGENXBIO

We are a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene